WDR11

Chr 10ADAR

WD repeat domain 11

Also known as: BRWD2, DR11, HH14, SRI1, WDR15

This gene encodes a member of the WD repeat protein family. WD repeats are minimally conserved regions of approximately 40 amino acids typically bracketed by gly-his and trp-asp (GH-WD), which may facilitate formation of heterotrimeric or multiprotein complexes. Members of this family are involved in a variety of cellular processes, including cell cycle progression, signal transduction, apoptosis, and gene regulation. This gene is located in the chromosome 10q25-26 region, which is frequently deleted in gliomas and tumors of other tissues, and is disrupted by the t(10;19) translocation rearrangement in glioblastoma cells. The gene location suggests that it is a candidate gene for the tumor suppressor locus. [provided by RefSeq, Jul 2008]

Primary Disease Associations & Inheritance

Hypogonadotropic hypogonadism 14 with or without anosmiaMIM #614858
AD
Intellectual developmental disorder, autosomal recessive 78MIM #620237
AR
0
Active trials
21
Pathogenic / LP
298
ClinVar variants
7
Pubs (1 yr)
1.8
Missense Z
0.53
LOEUF
Clinical SummaryWDR11
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
21 Pathogenic / Likely Pathogenic· 212 VUS of 298 total submissions
📖
GeneReview available — WDR11
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Moderate LoF intolerance
LoF Constraint
0.53LOEUF
pLI 0.000
Z-score 4.70
OE 0.38 (0.280.53)
Moderately constrained

More LoF-intolerant than ~75% of genes

Missense Constraint
1.80Z-score
OE missense 0.80 (0.750.86)
528 obs / 657.6 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.38 (0.280.53)
00.351.4
Missense OE0.80 (0.750.86)
00.61.4
Synonymous OE0.90
01.21.6
LoF obs/exp: 26 / 67.8Missense obs/exp: 528 / 657.6Syn Z: 1.17
LOF
DN
0.5477th %ile
GOF
0.3986th %ile
LOF
0.4627th %ile

The Badonyi & Marsh model scores dominant-negative highest, but genomic evidence most strongly supports loss-of-function (haploinsufficiency) as the primary mechanism.

LOF1 literature citation · 33% of P/LP variants are LoF

Literature Evidence

LOFTreatment with the Hh agonist purmorphamine partially rescues the WDR11 haploinsufficiency phenotypes.PMID:29263200

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

ClinVar Variant Classifications

298 submitted variants in ClinVar

Classification Summary

Pathogenic12
Likely Pathogenic9
VUS212
Likely Benign50
Benign10
Conflicting5
12
Pathogenic
9
Likely Pathogenic
212
VUS
50
Likely Benign
10
Benign
5
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
1
0
11
0
12
Likely Pathogenic
6
0
3
0
9
VUS
2
198
11
1
212
Likely Benign
0
4
23
23
50
Benign
0
0
10
0
10
Conflicting
5
Total92025824298

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

WDR11 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Gene2Phenotype Curations

WDR11-related intellectual disability and microcephaly

strong
ARLoss Of FunctionAbsent Gene Product
Dev. Disorders
G2P ↗

Gene2Phenotype curations · DECIPHER consortium patient cohort (public variants) · deciphergenomics.org

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Landmark / reviewRecent case evidence